8-K: Acurx Pharmaceuticals Announces Third Quarter 2024 Results and Provides Business Update

Acurx Pharmaceuticals reported its third quarter 2024 financial results, highlighted by progress in clinical trials and patent approvals for its lead antibiotic candidate, ibezapolstat.

Summary

• Acurx Pharmaceuticals announced its financial results for the third quarter ended September 30, 2024, along with a business update.
• The company's lead antibiotic candidate, ibezapolstat, is progressing towards Phase 3 clinical trials.
• A new patent for ibezapolstat was granted in July 2024, covering the treatment of C. difficile infection and gut microbiome health, expiring in June 2042.
• A request was submitted to the FDA in August 2024 for a meeting to review manufacturing processes for ibezapolstat.
• The company participated in several scientific conferences, presenting data on ibezapolstat and its preclinical program.
• Acurx reported a cash position of $5.8 million at the end of the third quarter, down from $7.5 million at the end of 2023.
• The company raised approximately $1.6 million through its ATM financing program during the quarter.
• Research and development expenses were $1.2 million for the quarter, a slight decrease from $1.3 million in the same period last year.
• General and administrative expenses were $1.6 million for the quarter, down from $1.8 million in the same period last year.
• The net loss for the quarter was $2.8 million, or $0.17 per diluted share, compared to a net loss of $3.1 million, or $0.24 per diluted share, for the same period last year.
• The company had 16,770,378 shares outstanding as of September 30, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and patent approvals, but the company's financial position and ongoing losses temper the overall sentiment. The company is making progress but is still in a high risk phase.

Positives

• The new patent for ibezapolstat provides a competitive advantage.
• The FDA meeting request for manufacturing review is a step towards Phase 3 trials.
• Ibezapolstat demonstrated comparable efficacy and safety to vancomycin in clinical trials.
• The lack of recurrence in ibezapolstat patients is a positive sign.
• The company has a complete roadmap for its Phase 3 clinical program and NDA filing.
• Acurx is developing a new class of antibiotics with a Gram-positive selective spectrum.

Negatives

• The company's cash position decreased from $7.5 million to $5.8 million.
• The company reported a net loss of $2.8 million for the quarter.
• The company has an accumulated deficit of $64.5 million.

Risks

• The company's ability to successfully complete Phase 3 clinical trials is subject to regulatory approval and other factors.
• The company's financial position is dependent on raising additional capital.
• The company's success is dependent on the successful development and commercialization of ibezapolstat.
• There are risks associated with the development of new antibiotics, including regulatory hurdles and market acceptance.

Future Outlook

The company plans to continue international regulatory filing initiatives in Q4 2024 and advance ibezapolstat to Phase 3 clinical trials. They also plan to develop an Anthrax bioterrorism program.

Management Comments

• Executive Chairman, Bob DeLuccia, highlighted that the company has a complete roadmap for its Phase 3 clinical program and NDA filing.
• Management believes the new patent for ibezapolstat will provide an important downstream competitive advantage.

Industry Context

Acurx is operating in the antibiotic development space, which is facing increasing challenges due to antibiotic resistance. The company's focus on a new class of antibiotics with a Gram-positive selective spectrum addresses a critical need for new treatments for difficult-to-treat bacterial infections, particularly C. difficile. The company is also exploring treatments for other gram-positive infections including MRSA, VRE and DRSP.

Comparison to Industry Standards

• Acurx's ibezapolstat is being compared to vancomycin, a standard treatment for C. difficile infection, and has shown comparable clinical cure and safety rates.
• The company's focus on a Gram-positive selective spectrum is a novel approach compared to broad-spectrum antibiotics, which can disrupt the gut microbiome.
• Other companies developing C. difficile treatments include Seres Therapeutics (SERE) with its microbiome-based therapy and Rebiotix (acquired by Ferring Pharmaceuticals) with its RBX2660 product. Acurx's approach is different as it is a small molecule antibiotic.
• The company's patent for ibezapolstat, expiring in 2042, is a significant competitive advantage, similar to other pharmaceutical companies that rely on patent protection for their products.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and progress in clinical trials.
• Employees are impacted by the company's financial stability and future growth prospects.
• Patients with C. difficile infection stand to benefit from the development of new treatment options.
• The company's suppliers and creditors are impacted by its financial health and ability to meet its obligations.

Next Steps

• The company will convene a meeting with the FDA regarding manufacturing processes in the fourth quarter.
• International regulatory filing initiatives will continue in Q4 2024.
• The company will advance ibezapolstat to Phase 3 clinical trials.
• Planning is underway for an Anthrax bioterrorism development program.

Key Dates

Keywords

ibezapolstat, C. difficile, antibiotics, clinical trials, FDA, patent, biopharmaceutical, ACXP, Gram-positive, DNA polymerase IIIC